MSP2372 Citations (1)
Originally described in: High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Keith Joung J Nature. 2016 Jan 6. doi: 10.1038/nature16526. PubMed Journal
Articles Citing MSP2372
| Articles |
|---|
| FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome. Schieber M, Marinaccio C, Bolanos LC, Haffey WD, Greis KD, Starczynowski DT, Crispino JD. Blood Cancer J. 2020 Oct 6;10(10):98. doi: 10.1038/s41408-020-00362-7. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.